Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Semi-OT: Another article re: Anambra politics with Offor mentioned.
http://www.sunnewsonline.com/webpages/politics/2006/nov/02/politics-02-11-2006-003.htm
Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw's Annual Healthcare Conference in New York
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov 3, 2006 - Advanced Cell Technology (ACTC), Inc. (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that Chief Executive Officer, William M. Caldwell, IV will be a featured presenter at Rodman & Renshaw's 8th Annual Healthcare Conference in New York City on November 6-8.
Mr. Caldwell will review ACTC's proprietary technologies and recent milestones in its mission to drive medically needed stem cell-based therapies to the clinic. He will discuss ACTC's stem cell-related technology platforms, and will spotlight the company's lead programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.
ACTC's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The Company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina.
The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.
The conference will take place at the Palace Hotel at 455 Madison Ave., in New York, NY. The ACTC presentation is scheduled for 11:40 AM in the Kennedy II room, 4th floor.
A live audio webcast can be accessed on the date of the presentation at www.advancedcell.com, and will be archived for 90 days. A downloadable copy of the presentation will also be available on the company's website at www.advancedcell.com/conference-presentations/.
For more information about the Rodman & Renshaw conference, visit http://www.rodmanandrenshaw.com.
http://www.pharmalive.com/News/index.cfm?articleid=388210&categoryid=63#
Just to be clear, AA, do you mean an upcoming pr from ERHC?
The ERHE board is fixed. Thank you!
See, there's the difference...I wasn't "bitching" about anything, I was trying to offer constructive feedback to assist in solving the problem. :)
No, it's not just you. Check the post # vs. total posts. See how it says "Post #57599 of 57598"? It's happening on other boards, too. Meatloaf is working on it, though.
Meatloaf is working on it right now. But, thanks anyway!
Posted by: Meatloaf
In reply to: rocky822 who wrote msg# 138 Date:11/3/2006 10:30:08 AM
Post #of 140
I'm looking at it now.
Thanks much!
Maybe, I'm not sure. I did a quick search of this board and couldn't find this exact content posted previously.
Nevermind, lbm, I found the answer. For others who are curious, here it is:
What is a derivative action?
A derivative action is a lawsuit brought by a shareholder of a corporation, on behalf of the corporation, to enforce a cause of action against a third party, such as an officer or director of that corporation. Derivative actions are brought when a corporation possesses, but does not enforce, its rights against third parties. It is often necessary for a shareholder to institute a derivative action because the corporation, which is run by officers and directors, will not bring a lawsuit against one of their own, even if there has been serious wrongdoing.
What types of charges are filed in a derivative lawsuit?
Derivative actions most often involve charges that officers and directors are wasting corporate assets, or that a corporation's management or board of directors breached fiduciary duties owed to shareholders by negligence, mismanagement or self-dealing.
http://www.blbglaw.com/html/secfaqs.html#eighteen
LBM, would you ask s. freed this question for me? (I'm not a member of the elephant boards.) Or can anyone else answer it? In re: to his position "If he does own a piece and he did not offre it to ERHC, the company may be forced to sue him to get what it should have received."
How could this ever happen? With EO as Chairman of the Board and Luca as acting CEO, who would initiate the "company" filing suit? Tia.
Done, thanks.
Meatloaf, it was suggested on the Q&A board that I bring this to your attention.
Dave had said that you guys were going to run a scan at 7am and 7pm to catch and fix the number sequencing problems on the boards. Well, I don't think the scan is catching whatever is causing the problem. The ERHE board was out of sync this morning prior to the 7am scan and is still showing one post # higher than total posts. Also, I'm occassionally getting "-1" on my favorites page.
Exactly. Did you notice if it was happening last night after the 7pm scan or before the 7am scan this morning?
Dave, I don't think the scan is catching whatever the problem is with the numbering. The ERHE board still says post # one higher than total posts. It was happening last night and still happening this morning after the 7am scan. And, occassionally, I get the "-1".
Goofy numbering again:
Date:11/2/2006 3:27:18 PM
Post #79398 of 79397
Paul, if you follow the link at the bottom it was released by The Heartland Institute today. And, I "found it" because I have "Advanced Cell Technology" as one of my favorites on my personalized news.google.com page. Therefore, anytime an article is released (by a company Google News follows) with Advanced Cell Technology somewhere in it, it comes up on my news page.
Ouch!
News Analysis: False Promises of Embryonic Stem Cell Research
The U.S. media tend to relay uncritically the claim that embryonic stem cell (ESC) research has tremendous promise to treat and cure many health conditions--but "promise" is the key word.
To date, no human being has even received ESCs experimentally, let alone as a successful cure of anything.
That lack of success puts tremendous pressure on ESC researchers and their allies to claim results where none exist, or at least to exaggerate what they have found.
The ESC tale told by Robert Lanza, medical director of Advanced Cell Technology (ACT), in the August 23 issue of the journal Nature is a typical and cautionary one.
The thrust of his claim--that ESC research can be done without killing human embryos--captured headlines worldwide. The idea was to create new ESC lines eligible for federal funding, because the ban on federal government money being spent on new ESC lines stems from the belief that as human life, embryos deserve special protection. Avoiding embryo death would theoretically satisfy persons who hold that belief.
But the headlines reporting Lanza's results were false.
Killing Embryos
In fact, however, none of the 16 embryos involved in Lanza's study survived. When a member of ACT's research advisory panel, Ronald Green, told The Washington Post, "You can honestly say this cell line is from an embryo that was in no way harmed or destroyed," he couldn't have been more dishonest.
From the media mania, you'd never know the Lanza publication was just a 200-word letter that spent as much verbiage on theory as actually describing the experiment. Nature had no business running it.
But as I've written elsewhere, Nature has long boosted ESC technology generally and the lifting of federal funding restrictions specifically, as has its American counterpart, Science. Their eagerness to run anything promoting this view recently led to Science being forced to withdraw not one but two "ESC miracle breakthrough" articles.
Lanza's team described its work in Nature as showing that a single cell pulled from the smallest human embryos (8-10 cells) can be made to divide in the laboratory to create a full cell line or "colony." Since fertility doctors often remove a single cell from embryos this age to screen for genetic defects before in vitro fertilization--though it's still unknown whether this will eventually harm the child--researchers could theoretically use these "spares."
Increasing Stock
But Lanza's team didn't just pluck one cell from each of the 16 embryos; they ripped them apart and used four to seven cells from each.
The ACT researchers' letter left the embryos' fate ambiguous, but an accompanying figure showed a photo of a biopsied embryo at a later stage of development--one Lanza's embryos never reached.
A longer Nature news release accompanying the article explicitly stated only one cell was removed and that all the embryos survived. (By press time for this issue of Health Care News, both the news release and Lanza's letter had been corrected.) ACT's news release declared repeatedly that the embryos survived.
Lanza also clearly lied in an audio interview for Nature, saying, "in this instance there is no harm to the embryo that we're biopsying." So did ACT CEO William Caldwell IV. "In this case," he told PBS's NewsHour, "we did not destroy the embryo."
Lo! After steadily declining for six months, ACT stock shot up 500 percent--making the already-wealthy Lanza and Caldwell much wealthier. Two days after the Nature report, ACT announced it had received commitments to raise about $13.5 million.
Defrauding the Public
Enter busybody Richard Doerflinger, associate director for policy development at the Secretariat for Pro-Life Activities of the United States Conference of Catholic Bishops (USCCB). In a detailed e-mail later posted on the USCCB Web site, Doerflinger showed step-by-step that Lanza did nothing new--except, perhaps, reaching new heights in scientific dishonesty.
To their credit, many in the media, along with other ESC boosters, have admitted ACT and Nature took them for a ride. U.S. Sens. Arlen Specter ( R-PA) and Tom Harkin (D-IA), authors of a bill President George W. Bush vetoed this year that would have expanded ESC research funding. were among those who admitted they were duped.
Specter, chairman of the Senate subcommittee that holds the health and medical research purse strings, told the ACT it had not accomplished "what you told the world." He added, "We have representation which created a lot of hopes ... and now they appear to be dashed."
Growing Funds
But ACT ethicist Ronald Green leapt to the company's defense. "The approach does not harm embryos; the experiment did," Green insisted. (Right. And "I didn't kill the victim," the shooter said; "the bullets did!") An utterly unrepentant Lanza tossed off the critical backlash as an indication of how politicized stem cell research has become.
Lanza has always been more salesman than scientist, constantly inveighing against the federal funding restrictions that slow the growth of his bank account. Yet the media treat him as an impartial source on all things stem cell--as they do with others who have made millions of dollars by hyping ESCs that, as you recall, have treated not one human being.
Many investors became instant millionaires when California's ESC research measure, Proposition 71, passed. Not coincidentally, supporters outspent opponents by 62-1. Because the text of the proposition ran to 9,000 words, voters couldn't possibly read it, and advertising and media coverage made all the difference.
Funding by Government
Meanwhile, adult stem cells (ASCs) are found throughout the human body, as well as in umbilical cords and placental tissue. First discovered in the 1950s at about the same time ESCs were, ASCs now cure or treat 72 diseases.
Bone marrow transplantation, for example, is actually a transplant of stem cells. They can also grow and repair organs, including patches of human skin (now commercialized) and heart muscle and blood vessels (still experimental, but advanced.) ASCs currently are being tested in more than 1,000 human clinical trials.
Because ASC medicine is so advanced, it attracts venture capital. Because ESC research is so speculative, with potential payoff horizons at least 10 years down the road, when it attracts venture capital at all it is probably not because of the research's merits but the hope of a sudden surge in federal or state funds. The ACT opened an office in California to take advantage of Proposition 71 funding.
Few areas of scientific inquiry are immune from fraud, but even fewer lend themselves to it as much as ESC research. Lanza's publicity effort is only one example, but it's enough to put us all on our guard.
--------------------------------------------------------------------------------
Michael Fumento (fumento@pobox.com) specializes in science and health issues.
http://www.heartland.org/Article.cfm?artId=19995
Semi-OT: Another article re: Anambra politics with EO mentioned.
http://www.vanguardngr.com/articles/2002/viewpoints/vp131102006.html
Impart Media Group's E&M Advertising Is Selected by Kitchen Labs for New Direct Response Promotion of 'The Fresh Box'
Monday October 30, 8:00 am ET
Direct Response Business Is Complementing New Media Advertising Space Efforts
SEATTLE, Oct. 30 /PRNewswire-FirstCall/ -- Kitchen Labs, an innovator in appliance technology, has announced the selection of E&M/Impart Media Advertising for the direct response promotion of "The Fresh Box," the vacuum seal, food storage unit. E&M/Impart Media Advertising is the direct response business unit of Impart Media Group (OTC Bulletin Board: IMMG - News), a unique full service provider of hardware, content, and advertising for digital media networks.
Ken Shafer, President of Kitchen Labs, said, "The Fresh Box represents such an innovation in food storage that it needs the power of direct response to show the consumer how it works and the benefits they will get from the moment they use it. We selected E&M because of their experience in direct response and in the kitchen appliance category."
Michael Medico, President of E&M/Impart Media Advertising, stated, "The ultimate goal of Kitchen Labs is to use direct response to generate profitable sales, but as we expand the promotion, the awareness we create will be instrumental in supporting the sale of "The Fresh Box" at retail. Kitchen Labs is one of 5 new agency client accounts using direct to consumer marketing to expand their businesses. E&M has launched an aggressive new business effort and the results have been very impressive. We are focused on contributing significantly to the revenue goals and strategic market positioning of our parent company."
About Kitchen Labs, LLC.
The innovative, North Carolina based company manufactures, non metal storage containers with electric vacuum pump for household and kitchen use, containers for storing food and other perishables and household items, containers for marinating foods, all featuring an electric vacuum pump. For more information, please visit www.kitchenlabs.com.
About E&M/Impart Media Advertising, Inc.
The New York City based, E&M/Impart Media Advertising, Inc. is the direct response business unit and wholly owned and operated subsidiary of Impart Media Group, Inc., headquartered in Seattle, Washington. Impart Media Group is a rapidly expanding digital signage leader in the emerging out-of-home media sector -- growing through a consolidation strategy -- developing the most advanced solutions to create a broad, integrated one-stop communications media company focused on digital signage and networked advertising offerings for leading brands and environments in industries such as retail, grocery, banking, restaurants, hospitality, government, airports, and public transit spaces, among others. E&M/Impart Media Advertising has been a leader in the direct response industry for more than 25 years with broad experience in acquiring new customer for clients in the entertainment, finance, insurance, retail, healthcare, music, travel, drive to web and more. For information please visit: www.impartmedia.com or call (800) 544-3343.
CONTACT:
Rick Lutz, LC Group
(404) 261-1196 or LCGroup@mindspring.com
Andrew Hellman
CEOcast, Inc.
(212) 732-4300
Art, did you see this link posted by Meridian on IV? Excerpt below:
http://www.stimmel-law.com/articles/Corporate_Opportunity_Doctrine.html
CORPORATE OPPORTUNITY DOCTRINE: THE BASICS
An employee, a director, and/or an officer of a corporation owes a fiduciary duty to the corporation, as discussed in detail in the linked article above. Part of that duty is that they cannot seize for themselves a business opportunity that would otherwise go to the corporation’s benefit. This is true whether or not the opportunity was discovered while performing duties for the particular corporation.
A typical example will best illustrate how this theory works. Assume you are a sales manager for Company X which sells oranges. Assume you discover that a vendor of oranges is in economic trouble and willing to sell the product for a fifty percent reduced price. The company you work for has sufficient funds to purchase the oranges and customers waiting to buy them.
You cannot purchase the oranges for your own account. You cannot refer the vendor to another entity and hope to receive a commission or some other benefit. You cannot purchase the oranges and resell them to your own entity for a markup.
The reduced price oranges are a corporate opportunity and if the fiduciary takes it he or she may be personally liable to the corporation for the lost benefit.
What is required to create the violation of the corporate opportunity doctrine? What happens if the company you work for is not interested in those oranges or does not have the financing to buy them? What precisely is needed to constitute a violation of the doctrine?
Under this doctrine, one who occupies a fiduciary relationship to the corporation is prohibited from acquiring, in opposition to the corporation, property or rights in which the corporation has an interest or tangible expectancy or which is essential to its interest. Kelegian v Mordichian (1995) 39 Cal. Rptr. 2d, 390; 33 Cal. App. 4th, 982.
“The “corporate opportunity” cannot be taken by one occupying the fiduciary relationship with the corporation when the proposed activity is reasonably incident to the corporation’s present or prospective business and is one in which the corporation has the capacity to engage. Ibid.
Whether or not a given opportunity constitutes a corporate opportunity is a question of fact to be determined from objective facts and surrounding circumstances existing at the time the opportunity arises.
In determining whether an officer may take advantage of a business opportunity in which the corporation is interested, the courts will consider whether the corporation had an interest, actual or expectant, in the opportunity and whether acquisition by the officer would hinder or defeat the plans of the corporation in carrying on or developing legitimate business for which it was created and, additionally, the courts may consider whether the corporation has the financial resources to take advantage of the particular opportunity. Thompson v Price (1967) 251 Cal.App.2d 182, 59 Cal. Rptr. 174.
Stem cell stock run may be short after elections
14:53 ET, Fri 27 Oct 2006
[-] Text [+]
By Bill Berkrot
NEW YORK, Oct 27 (Reuters) - Investor optimism that U.S. embryonic stem cell research restrictions may ease if Democrats win control of Congress in the upcoming elections is boosting shares of companies that specialize in the controversial technology.
But health industry analysts caution that any price rise following the vote may be short-lived as investors find that marketable products, such as cures for neurological diseases or spinal injuries, may be years away.
Wall Street analysts expect an immediate and pronounced bump to already surging stem cell stocks, such as Geron Corp. and StemCells Inc., and others in the field if Democrats regain control of the U.S. Congress.
"The entire stem cell space will benefit from the easing of restrictions, primarily because the stem cell potential will be in the media and there will be news flow," Rodman & Renshaw analyst Ren Benjamin said.
Benjamin was referring to companies working with adult or cord blood stem cells as well as those dealing with the embryonic cells associated with the fierce anti-abortion debate.
The furor was revived when popular actor Michael J. Fox, who suffers from Parkinson's Disease, starred in a controversial ad supporting candidates who favor stem cell research.
Conservative and religious groups, meanwhile, are working hard to rally their flocks to oppose both laws that would lift federal restrictions and candidates who favor stem cell research.
Groups opposed to the technology may still be able to count on U.S. President George W. Bush to stall new initiatives into embryonic cell research. The only veto of his administration has been against a bill expanding federal funding for research in the field.
Steve Brozak, an analyst for WBB Securities who made an unsuccessful run for Congress in 2004, agreed that shares of any company associated with stem cell research, whether embryonic or not, stand to gain in the short term from an election in which Democrats win back power in Washington.
"People will say, 'Well, it's a stem cell company, so let me invest,'" Brozak said.
Some companies involved in stem cell research have already seen their shares rise this month.
Geron, whose shares have gone up 28 percent since Oct. 2, would be the clear and immediate corporate beneficiary of the lifting of embryonic cell research restrictions, analysts said.
"They are the ones that have the preponderance of intellectual property, which provides you freedom to operate, and they have the know-how in the field, which gives you the ability to realize commercial applications," Brozak said.
Benjamin, the analyst, also mentioned tiny Advanced Cell Technology as a likely winner from renewed funding in embryonic stem cell research.
Analysts said companies involved in other types of stem cell research that could see an influx of investor money include ThermoGenesis Corp., which harvests adult and cord blood stem cells, Cytori Therapeutics Inc., which also works with adult stem cells, and Osiris Therapeutics Inc., which began publicly trading in August.
Others small players that stand to gain from a lifting of restrictions include Aastrom Biosciences Inc., StemCells Inc. and ViaCell Inc., Benjamin said.
"I would say there would probably be an initial rush of excitement from investors and then a cooling-off period," Benjamin predicted.
He said there would likely be another surge in investments if research funding dollars start to get distributed.
"Even if they get some grant money, that doesn't automatically translate into a product," Benjamin cautioned. "That's going to take some time."
Iwondertoo, I think this is where Joe got his info re: Starcrest being in Texas. I have no idea if there's a connection between Starcrest Energy and the Starcrest that just did a deal with Addax. (I tried calling the number and it was a machine.)
FWIW, I have no if idea Starcrest Energy has ANYTHING to do with the one we are looking for but I did find this and imagine this is probably where Joe got his info from.
Consulting
TOP>Consulting > Starcrest Energy
Starcrest Energy
Starcrest Energy
2313 Coit Rd #D
Plano TX 75075
Phones: (972) 596-7944
http://www.e-pages.com/glblyellow/business.php?state=TX&b_id=645342&c_path=14527%2C14483
Then, I googled the number and came up with this:
NORTHCREST PIPELINE, LTD.
MR. JOHN P. SNIDER
PRESIDENT
2313 COIT ROAD, SUITE D
PLANO TX 75075
972/596-7944
http://www.rrc.state.tx.us/divisions/gs/2002ar/tabl11.pdf
And, I'm a little unclear in your post if you think that M (I'm assuming Meridian) is the one who writes the blog. As far as I know he is not. That's another poster who I think goes by procon on Ihub but writes on the blog as Joe Shea.
SaltAire Selects Impart Media Group's E&M Advertising for New Direct to Consumer and Retail Support Campaign
Posted on : Thu, 26 Oct 2006 12:16:00 GMT | Author : Impart Media Group, Inc.
SaltAire(R) Sinus Relief is a specially formulated drug free solution developed by leading sinus and allergy specialists to clean and moisturize nasal passages. The promotion is scheduled to begin testing this month.
Tom Petrocine, Marketing Consultant for SaltAire, said, "The SaltAire(R) Sinus Relief formulation is so unique and effective that direct response represents the most cost effective way to communicate with sufferers of chronic sinusitis and allergies."
Michael Medico, President, E&M/Impart Media Advertising, stated, "SaltAire is well positioned to take advantage of all what direct response advertising has to offer, due to the availability of the product at retail, as well as offering the convenience of ordering direct. The awareness of SaltAire and the benefits inherent in the product are effectively illustrated and we are very excited about the opportunity. SaltAire is one of 5 new agency client accounts who will be using direct to consumer marketing to grow their businesses. E&M has launched an aggressive new business effort and the results have been very gratifying, as we continue our accelerated integration into Impart and substantiate our strategic revenue and market value."
About SaltAire
SaltAire(R) Sinus Relief developers and New York Sinus Center founders Drs. Scott Gold and Robert Pincus have routinely recommended their chronic sinusitis patients rinse their nasal passages with a buffered hypertonic saline solution. While the nasal rinsing significantly relieved their patients' symptoms, many found it difficult to measure out and mix the required ingredients each morning as recommended. At that time, no convenient and effective delivery systems existed, for such a solution.
Once the pre-mixed SaltAire solution became available through their practice, Drs. Gold and Pincus discovered patients were very enthusiastic about the product's effectiveness and ease of use. Provided with the pre-mixed solution -- bottled in an easy-to-use dispenser -- patients said they followed the recommended daily treatment more closely and experienced, as a direct result, great relief from their symptoms. Inspired by these success stories, Drs. Gold and Pincus decided to make the product more widely available in early 2000. SaltAire(R) Sinus Relief is now available, without a prescription, in more than 5,000 independent and chain pharmacies across the U.S.A.
Lady, check out FTK. They're up 22% since announcement but they're still far from their 52 week high of $30.75.
I haven't followed FTK but right now suppliers (RIG, HAL) to oil industry are up significantly.
FLOTEK INDUSTRIES, INC. ANNOUNCES RECORD 3RD QUARTER EARNINGS OF $0.40 PER SHARE
HOUSTON, October 24, 2006 - Flotek Industries, Inc. (AMEX: FTK) announced record net earnings for the quarter ended September 30, 2006 of $3.5 million or $0.40 per common share ($0.37 per diluted common share). These results compare with third quarter 2005 net earnings of $1.8 million or $0.24 per common share ($0.21 per diluted common share). This near doubling in net earnings was driven by higher sales volumes and increased operating margins in all three core business lines.
Sales in the third quarter 2006 were $29.2 million, an increase of 119% compared to $13.3 million for the third quarter 2005, and a 32% increase compared to the second quarter of 2006. The third quarter of 2006 included the full quarter revenue contribution of three drilling tool acquisitions completed in August 2005 and January 2006 and two artificial lift acquisitions completed in the second quarter of 2006. These acquisitions contributed approximately $7.1 million in revenues for the third quarter 2006. In addition, continued strong organic growth in Chemical and Logistics raised sales in the third quarter of 2006.
Income from operations for the third quarter of 2006 was $6.0 million, an increase of 119% compared to $2.7 million in the third quarter 2005, and a 61% increase from the second quarter of 2006. Following are the results of operations by segment.
Susie, check and see if the total posts count is off by one. For example, go to the last message on the board, and see if it looks like there's another post but you can't go to "next".
When I've seen this happening before, I've just posted the board link to Dave and he somehow resets it.
MSNBC.com
Political bloggers coordinate 'Google Bombs'
Readers are urged to 'fight fire with fire'
By Heather Greenfield, Technology Daily
National Journal
Updated: 5:00 p.m. ET Oct 25, 2006
The 2006 campaign is about to be "Google-bombed." Both liberal and conservative bloggers have embarked on plans to manipulate the Google search engine so that negative articles about the candidates they oppose appear near the top, potentially influencing undecided voters.
Liberal bloggers had the idea first. Chris Bowers of MyDD outlined the strategy Sunday. He said the plan involves purchasing "Google AdWords that will place each negative article on the most common searches for each Republican candidate. Simultaneously, I will produce an article on MyDD that embeds that negative article into a hyperlink."
Bowers asked bloggers to help add links, and they spent the next few days compiling negative news articles on Republican candidates in about 50 targeted races.
Conservative blogger John Hawkins of Right Wing News learned of the strategy and urged his allies to "fight fire with fire." Hawkins expressed concern the Google-bombing campaign just might work for Democrats.
"Who would be doing a Google search on a particular candidate in the final days of a campaign?" he wrote. "Probably an independent voter who is trying to get more information about a candidate. And if the first article he runs across is a brutal hit piece, well, that could be the information that helps him make up his mind."
Pete Leyden, director of the Democratic think tank the New Politics Institute, just published advice on search-engine strategy. "It will definitely work," he said. "So few people are buying political search ads [that] a blogger can get it for literally pennies per eyeball."
"It's a very smart move," Leyden said.
Jeff Mascott of Rightclick Strategies, who advises clients about online strategies, said buying Google AdWords and placing them "is a very cost-effective way in reaching an individual." But he also said that with Google updating its search criteria every 30 days, the Google-bombing campaign likely would not work in time for the election.
Mike Connell of Connell Donatelli Inc., online strategists for conservative candidates, agreed. "It may not be too little, but it may be too late," Connell said.
Google is not thrilled by the idea. "We don't condone the practice of Google-bombing or any other action that seeks to affect the integrity of our search results," spokesman Ricardo Reyes said. He added that such campaigns are not impossible but are unlikely to be effective given the complexity of the Google search algorithm.
Before the bombing campaign, a Google search of Sen. George Allen, R-Va., found a Washington Post article about of his alleged racially disparaging remark just below his campaign Web site in ranking. A search of Sen. Conrad Burns, R-Mont., also found mostly negative articles among the top 10 sites anyway.
Kari Chisholm, a Democratic new media strategist for one of Burns' opponents who lost in the Democratic primary, doubts that the Google-bombing campaign will be very useful. "It's not about chasing the 1 percent of voters that haven't figured out there's a difference between [Democrat] Jon Tester and Burns," Chisholm said.
Copyright 2006 by National Journal Group Inc.
URL: http://www.msnbc.msn.com/id/15418130/
--------------------------------------------------------------------------------
Debate in Missouri heating up before election. This from Newsweek but no mention of ACTC.
http://www.msnbc.msn.com/id/15415763/
Dr. Robert Lanza Receives 2006 'All Star' Award for Biotechnology
Oct 24 2006, 9:30 AM EST
BIOWIRE
One of the world's leading authorities on embryonic stem cells, Robert Lanza, M.D., VP, Research and Scientific Development for Advanced Cell Technology, Inc. (OTCBB: ACTC) will be honored at the 11th Annual Mass High Tech All-Star Awards Networking Reception, October 25th from 6:00-8:30pm at the Westin Boston Waterfront Hotel.
Dr. Lanza is the honoree for the category, Biotechnology; a complete listing of honorees and further details can be found at http://masshightech.bizjournals.com/masshightech/event/2544.
Robert Lanza, M.D., has over 30 years of medical research experience, and has authored/edited 18 books, including "Essentials of Stem Cell Biology" and the "Handbook of Stem Cells" (as Editor-in-Chief). Last month, Dr. Lanza served as senior author for a paper that appeared in the journal Cloning and Stem Cells, in which ACTC scientists and their collaborators rescued visual function in animals using retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. In August, Dr. Lanza served as senior author of a paper in Nature, describing a method for deriving stem cells using a single-cell approach that does not harm embryos.
He is a former Fulbright Scholar, and studied as a student in the laboratory of Jonas Salk (The Salk Institute), Richard Hynes (MIT), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his undergraduate and medical degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.
Art, thanks for the compliment but I'm really not doing extensive dd here. I simply have "Emeka Offor" as one of my searches on Google News, so whenever a new article is published, it just shows up on my personalized news page.
And, for anyone who hasn't tried this new feature of Google's, you should consider it. You simply go to news.google.com and set up a personalized page. Some that pertain to erhe that I have listed are "nigeria jdz" and "erhc". You can also sign up for alerts to be emailed to you when there's news.
It really is fairly simple although it may take a little while to get your settings the way you want them.
Semi OT: Another Anambra politics article with Offor mentioned:
http://globalpolitician.com/articledes.asp?ID=2251&cid=8&sid=55
Thanks, Lady, that's the piece I was missing. As always, I appreciate the time you take to help.
Advanced Cell CEO tackles stem cell debate
By David Morrill, Business Writer
Inside Bay Area
Article Last Updated:10/22/2006 09:59:23 AM PDT
Q: For those who don't know, can you describe Advanced Cell Technology and explain what it's trying to do in the field of stem cell research?
A: Advanced Cell Technology is focused on the field of regenerative medicine. In essence what that means is the field of the aging of the body, and how we can address some of the diseases that occur with a therapy that we have chosen, which is the embryonic stemcell therapy that we are trying to derive here.
Q: What potential developments could come from your stem cell research?
A: Our platform development is a technology by which we can derive cells that are almost magical because they produce any specific cell in the human body. Because you differentiate them, you can produce those specific types of cells in the early stage of life so you can inject them in an area as they are defined, and they can then work their magic in terms of addressing disease areas that correspond to the cell type. For example in the area of the eye, there's a cell type called the RPE cell, retinal pigment epithelium. And that cell we believe can help deal with retinal diseases.
Q: Other companies are focused on stem cell research. What makes Advanced Cell Technology unique?
A: First of all, the people at Advanced Cell were there at the very beginning. Secondly, it has been our only focus from day one. Whereas others have either come into the field from another area, or have other areas they are also developing, this is our sole focus. There are very, very few companies that I know of that have been around as long as we have that have spent the time, money and energy to develop the company to what it is today.
Q: As a public company, you get pressure from shareholders to generate revenue quickly. As a biotech company, you need to understand the importance of patience and that products take time to develop. As CEO, how difficult is it for you to balance those issues?
A: This is something that is really unique when compared to other industries. As a development company, you're basically at the whim of your capabilities to raise capital. And, of course, you have all sources for that. And one of the advantages of being public is that your options are a little broader compared to if you are private. Biotech companies right now in general have been underweighted by portfolio managers. I think that will change, and money will flow back into the sector and everyone in the sector will benefit.
Q: Earlier this year, Advanced Cell Technology became the first company that focuses in stem cell technology to relocate its headquarters from out of state after California voters passed Proposition 71 in 2004. What were some of the reasons behind the move?
A: One of the magic issues that has driven the U.S. economy is that the government funds basic research, and then the venture capitalists and others begin to incubate some of the nuggets that can be commercialized. Well, that process evolved into some tremendous technology platforms. But in the case of stem cell research, the government decided not to, so the funding for this has been somewhat limited. When California voters decided to fill that void by passing Prop. 71, it was very apparent that if you were going to become a player in this industry, you had to be in an area where this capital would be deployed. We feel we bring some unique advantages to California because we have all this body of stem cell research. We know not only what certain processes need to be done, but we know what we shouldn't do. And we can take that and share it with the institutions here in the state of California.
Q: What opportunities do you see Advanced Cell being able to take advantage of with Proposition 71?
A: I think there is a lot of research that we just physically and economically cannot do. ... If you look back at Silicon Valley, with the introduction of the microchips way back in the'70s, we've come a long way in terms of chip technology. We have the same issues here in biotechnology. We have certain platforms, in terms of deriving stem cells, that we'll look back at in 10 years and laugh at because they were so laborious, expensive and in some ways unpractical compared to what has happened over those 10 years.
Q: How will the fate of the funds from Proposition 71 impact ACT?
A: In part, these funds are really focused on nonprofit institutions, but we have collaborated with some of them and supported their efforts, and in that regard we will be kind of contributing to research efforts of their application. I'm under the impression that there will be a second wave of grants coming out near the end of the year that will address for-profit companies and specifically focus on this issue of translation.
Q: How has your report on generating human embryonic stem cells without harming embryos, the media attention and subsequent backlash affected your company? Where do you go from here?
A: There are several impacts that it has had. First, it has raised the profile of our company, which has created more liquidity in our stock. Second, just by the nature of that, it has allowed existing shareholders to reinvest in the company, which they did. And third, the strategy that was employed behind the research was to try and meet the standards by which President Bush had set the bar, if you will, for funding by the government. And we firmly believe that has been met, and we have seen responsible scientists and responsible publications affirm the fact that this appears to be something that needs to be considered. We believe we've met that standard.
Q: Some felt misled because embryos used in your research were ultimately destroyed. How would you respond?
A: Very simply. The experiment was not about whether embryos were destroyed or not destroyed. The experiment was designed to specifically determine whether if you extracted a cell realizing a well-known technique, can you create not only the test it was designed for, but also a new line which was an embryonic stem cell line. Everything else is already the state of the art. It was amazing when you read the national press about the subject when it came out. All of them got it right.
Q: What do you believe you have accomplished and what do you see as its significance?
A: We believe very, very strongly that we've developed an alternative method by which stem cells can be developed, meeting the bar that the president set up back in August of 2001, where he said he didn't really want to fund any future stem cell lines where the embryos would be destroyed. We now have a capability to develop stem cell lines without destroying the embryos. And to the extent that people do that, the resultant stem cell line that would be developed after a birth of a child, those lines should be made available for researchers to have funding from the U.S. government.
Q: Sen. Arlen Specter, a proponent of stem cell research, told your vice president, Robert Lanza, "It's a big black eye if scientists are making false and inaccurate representations." Later he said you may have set back the movement to fund embryonic stem cell research. How would you respond?
A: I look at the qualifier. The senator was very careful in terms of how he said what he said. I'm not sure what his mission was. He asked us to come down and to testify, and he didn't tell us he was going to have this preamble ahead of time. Despite what the senator tried to do, Dr. Lanza basically indicated to the senator that this is important work and that while we all support his bill, we are not going to sit by and wait. We are going to try to do everything possible to develop this technology and industry so we can have funds flow into it. We supported the bill, and we will support any other technology that comes out, but we are also going to try and develop something we know we can do, which is this particular technology. In the final analysis, even the other people that were testifying didn't discredit the work. He wants his legislation to pass. And one can speculate that the senator is maybe concerned that people won't support his legislation because they feel there's an alternative. I think that would be a very unfortunate situation. I think we should not only support his bill but anything that would support funding into this area.
Q: Some people strongly oppose stem cell research, with one of the most vocal being President Bush, because they say destroying embryos for research is morally wrong. Do you think your research addresses their concerns?
A: I don't believe President Bush is opposed to the research. If we can put his position in perspective, the first seven or eight months in office when he gave his first major address it happened to be in this area. His opposition happens to be a moral issue in this area. What he did at that point in time is to say all lines to that date he was going to let be funded. He was led to believe that their may be 60-plus lines available. No one at that point didn't know that they would all be contaminated and that there were only 21 lines not 60. So in the five years that ensued, you had a situation where the facts were different than what he made his decision based on. The president did state that he was very troubled with the moral issue that some people had, and he would like to see technology be developed that would not destroy the embryo. And so we feel we have developed that technology for him. I don't believe President Bush has ever come out and said he was against stem cell research. He's just against the methodology, and he's put up a big caution against it.
Q: There's a lot of politics when it comes to stem cell research. How confident are you that your industry can overcome these roadblocks and turn out results from the research that the public demands?
A: I'm confident enough that I'm putting my time and energy into this company. I think the controversies we see today, like all others, will go away as soon as the first patient is cured, so that in five years time we will be talking about the next great cure coming down from some company that has yet to be defined because of the benevolence of California. With that money flowing in, you're going to be seeing a lot of new young companies sprouting up and they're going to be involved in developing therapies with larger companies, and we're just going to find all sorts of wonderful solutions to some of the ugliest diseases we see today.
http://www.insidebayarea.com/business/ci_4532596
Lady, hoping for some help here. I have no experience with IPO's and was researching TRBN.
Here, I see that they were issuing 4 millions shares as of 10/18.
Trubion Pharmaceuticals, Inc. is offering 4,000,000 shares of its common stock. This is our initial public offering, and no public market currently exists for our shares.
http://sec.freeedgar.com/displayHTML.asp?ID=4708281
Yet, here it shows almost 17 million outstanding.
Shares Outstanding 16,906,000
http://quotes.nasdaq.com/asp/summaryquote.asp?mode=&kind=&symbol=TRBN&symbol=&symbol...
Then, I was wondering about the insider holdings:
Number of Insider Trades: 7 7
Number of Buys: 7 7
Number of Sells: 0 0
Net Activity: 3,802,516 3,802,516
Total Shares Traded: 3,802,516 3,802,516
Number of Shares Bought: 3,802,516 3,802,516
Number of Shares Sold: 0 0
So, I was originally confused as I was seeing 3.8 million held by insiders (out of 4 million) and couldn't figure out where Wyeth's 800k went.
Here's list of insiders.
http://finance.yahoo.com/q/ir?s=TRBN
I guess I'm missing something that shows where they upped their initial offering?
I'm actually just confused and am hoping you can steer me in the right direction. Thanks much!
Semi-OT: Article re: Anambra politics with Offor mentioned.
In Anambra, the Demons are Back
Simon Kolawole Live!, Email: Simonkolawole@thisdayonline.com, 10.22.2006
True, there are some things one can understand in life and there are some things one cannot. I can never understand the trouble with Anambra State. And to play safe, I would rather think the state is operating under a curse. It looks as if one irreparable and irrevocable curse has been nailed on the state. It is as if someone has locked the door to peace and progress in the state and thrown the key into the Atlantic Ocean. The state takes one step forward and immediately takes ten backward. Pronto, a directory of impeachable offences was rolled against Mr. Peter Obi, the state governor.
Knowing fully well that if Obi is impeached, his deputy, Dame Virgy Etiaba, would take over and keep APGA in government, the House decided to drag her to the impeachment guillotine too. That way, the Speaker, Mike Balonwu of the PDP, would become “acting governor” and hold fort. What a shame. If the people of Anambra are not ashamed of themselves, they need to employ the services of other Nigerians to be ashamed on their behalf. As one crisis is quenched, another is born. The state lives in perpetual crisis. The demons tormenting the state appear to be insatiable. They eat flesh, they drink blood and yet their burning hunger cannot be extinguished. Right from the time of Dr. Chinwoke Mbadinuju and Emeka Offor, to the time of Dr. Chris Ngige and Chris Ubah, the demons are crying: more blood, more blood.
I don’t know how many states in Nigeria can boast of a better collection of authentic heroes than Anambra State. Not just authentic heroes, but men and women who have distinguished themselves in their fields and can stand shoulder-to-shoulder with their contemporaries anywhere in the world. Check out the list, if you are in doubt: the late Dr. Nnamdi Azikiwe, a genuine African hero and patriot; Dim Odimegwu Ojukwu, though seen as a rebel by outsiders, but a rebel with a cause; Chinua Achebe, probably the best African novelist; Professor Dora Akunyili, a giant among equals; Chief Emeka Anyaoku, diplomat extraordinaire; Dr. Alex Ekwueme, an uncommon politician; Philip Emeagwali, Africa’s foremost scientist; the late Dr. Pius Okigbo, an accomplished economist, and several other distinguished people I dare not try to list if we are to finish this discussion today. Why is Anambra so blest? Why is Anambra so cursed? What makes it possible for touts—both the educated ones and their street counterparts—to hold the state by the jugular all the time? Why do these demons always have their way?
The latest crisis—a storm, you would say, in the teacup—has again brought out the vulnerability of democratic principles to manipulations. The House of Assembly has every right and duty to impeach Obi if he is found guilty. However, on the surface, it would look like the House is actually trying to discharge its constitutional duty. After all, according to the impeachment merchants, they want to fight corruption. “Anti-corruption” is the hit song in town and it is very common nowadays for everybody to fight corruption as conveniently as possible. If you want to commit murder and get international recognition, just say you are fighting corruption. If you want to commit rape and get a national honour, just say you are fighting corruption. If you want to assault the constitution, ridicule the judiciary—the last hope of the common man—and get applause from eminent constitutional lawyers, just say you are fighting corruption. The anti-corruption war has been so politicised, so bastardised and so cannibalised that even respected people in the society are ready to applaud a glaring assault on the rule of law just to get at their opponents. Anybody who queries the warped anti-corruption moves is automatically classified as supporting corruption.
Those who have been watching the latest Anambra horror movie will know for sure that the devils are back to work. Between 1999 and 2003, it was the gory dance between Mbadinuju and Offor. While states like Bauchi and Jigawa were making progress in infrastructural development and Information Technology, Anambra was under the spell of Bakassi Boys and other demons. Godfathers and their grandsons were strangulating the state. It got so bad teachers were owed salaries for months and they went on strike. Anambra students couldn’t take their school certificate examinations because of this. Those who were rich enough relocated to neighbouring states to register and take their exams. But the demons were smiling to the bank while the state was rotting away. They would not give a damn. Then, you ask yourself: Is this the same state that produced the Great Zik? What’s going on here?
As if that was not enough trouble, Dr. Chris Ngige of the PDP was anointed by the demons to take over the state in 2003, even though it was glaring to the blind that the election was won by APGA. However, Ngige became a hero. Not because of any outstanding achievement, but for his refusal to hand over the state treasury to the demons who openly said they had entered into an agreement with him to hand over the keys of the treasury to them. In the most bizarre incident, he was abducted by his traducers who made no secrete of their actions because of their closeness to “Abuja”. They flaunted this morbid credential. The police became their accomplice. Yet, Ngige stood firm. And for that, I will continue to doff my heart for him any day. The height of the insanity was in November 2003 when, in a bid to force the Senate to ask Obasanjo to declare a state of emergency in Anambra, the Abuja-backed tormentors organised a three-day mayhem, under the watchful and protective eyes of men of the Nigeria Police Force, in which property worth billions of naira were destroyed. A Senate committee was “mobilised” to go and write a damning report calling for the declaration of state of emergency in Anambra. Again, Ngige survived. In all this, the state security agencies did not deem it fit to invite these demons for questioning, even if for the records. Instead, they watched blissfully. When an antelope is dancing by the roadside, the drummer is somewhere in the bush. We all know the drummer in this case.
When Peter Obi won his case at the Court of Appeal, I felt a sort of relief. Not that I had anything against Ngige, but my reasoning was: if this would finally bring peace to the state, then it was a sacrifice worth the while for Ngige. But, obviously, I was mistaken. The demons can never be appeased. They are back in full force. They want more blood. Despite the fact that Obi has articulated a clear development agenda for the state, despite all the goodwill he is beginning to generate for the state from far and wide, despite his attempts at transparency with the publication of quarterly programmes with clear time-table for implementation, despite his efforts at creating law and order in the state so that the environment can be conducive for development, the demons are out for him. They want power at all costs. They want more blood. I even understand he has been accused of non-performance. In six months? If governors are to be judged by six months in office, I bet there will be no governors in the world again.
In the last two weeks, events have rushed themselves. Just before Obasanjo’s visit, the rumour mill rolled out stories that impeachment was on the cards. A female APGA member of the House decamped to PDP, apparently in preparation for the impeachment charade. (Ironically, INEC is yet to declare her seat vacant and fix a date for bye-election, unlike in the Plateau State case. Of course, we know who issues instructions to the “independent” commission. We know whose interest they are serving. They are all fighting corruption.)
Suddenly, the motion to impeach Obi was moved and seconded. To align the move with the anti-corruption gimmick, all sorts of charges were brought against him. I want to re-iterate for the 1000th time that I fully support any genuine efforts to fight corruption. However, if the move against Obi is a sincere anti-corruption effort, then I am the Queen of England. The game is just too clear for anybody to play games with our sensibilities. We know the motive. We know the masterminds. We know them through and through. We have seen all this before. Obi can defend himself, so I do not intend to defend him here. He has said: “If any kobo belonging to Anambra State has been embezzled, I should be held responsible. I am ready to pack my suitcases and leave the government house.” Offences have to be contrived and infringements have to be manufactured in order to hang an innocent man and pave the way for the demons to take charge of Anambra State again. Every Anambra indigene should be worried. Every Igbo person should be disturbed. Every Nigerian should be concerned.
I blame Obi for one thing. Is this not the same House of Assembly that withstood the Abuja-backed gangsters for three years under Ngige? How come they are now glove-in-hand with the same demons? I think the first thing Obi should have done was to court Ngige rather than fight him. They have common enemies who are bent on capturing Anambra for selfish purposes. But Obi allowed this opportunity to slip through his fingers. It is inconceivable that the same House of Assembly that stood firm against these tormentors is now working with them shamelessly. Something is terribly amiss. It is easy to say it is because Obi has refused to “settle” the House members like Ngige did, but I think it is much more than that. I just cannot put my finger on the reason for this U-turn.
Let me try to picture what will happen next: the House will instruct the Chief Judge to set up an impeachment panel. They will give him a list full of Ubahs. If the CJ uses a different list, he would be accused of not appointing people of “unquestionable” character. He will be suspended. An acting CJ will be appointed. His own list will be full of people of “unquestionable” character (which means the governor’s opponents). The panel will sit for one minute and declare Obi guilty. Balonwu becomes governor. Bayo Ojo will kick against it. The president will declare a state of emergency and appoint a sole administrator. But, as we all know, even the best-laid plans can go wrong. Woefully.
I can't find any reference to Perry Leopold on that site. Is he just a poster? Or does he have some affiliation with the site? Do you have to pay $15/month just to read the posts? Does he post about Enterayon? Other mining stocks? What about his posts led you to invest in this company?
And, is he the Perry Leopold, musician from the 70's?
I'm the one that originally asked Gump about this company. I asked someone who I thought knew alot about Canadian mining for his opinion about this company's acquisitions. He referred me to a "real" expert, Gump.
Whether you like his opinions or not, Gump knows mining and he knows Canadian mining.
And, I'm not 100% sure but I think Perry Leopold's famous for being an acid rocker in the 70's. I haven't been able to confirm this and I also haven't been able to confirm where his mining experience comes from.
http://www.lysergia.com/LamaReviews/reviews1.htm#PERRY%20LEOPOLD:%20Christian%20Lucifer
It looks like this is a "perspective" inset into a larger article called "Stem Cell Politics". I can't get the whole article as I don't have a subscription. But, here's the link so you can see what I'm talking about.
http://content.nejm.org/cgi/reprint/355/16/1634.pdf
Single-Cell Storm
Susan Okie, M.D.
Perspective
by Okie, S.
Scientists at Advanced Cell Technology, a California company, reported in August that a single cell taken from an eight-cell human embryo can sometimes be coaxed to produce embryonic stem cells, suggesting that such "biopsies" might be a way to generate new stem-cell lines while preserving embryos.
The report, published online by the journal Nature,1 stirred up considerable controversy, in part because both the journal's initial press release and a podcast interview with senior author Robert Lanza gave the impression that two new lines had been created without destroying any embryos. "What we have done, for the first time, is to actually create human embryonic stem cells without destroying the embryo itself," Lanza said in the podcast.2 On the contrary, all 16 donated embryos used in the study were destroyed during the experiments, a fact that was stated, although not emphasized, in the article. A total of 91 cells (called blastomeres) were individually removed from the early-stage embryos and were cultured, in most cases in dishes with other blastomeres. Two of the blastomeres gave rise to embryonic stem-cell lines. The results — together with unpublished work by the authors — suggest, in principle, that single-cell biopsies (which are done on some embryos in IVF clinics for preimplantation genetic diagnosis) could be used to derive stem cells without destroying embryos.
Nature issued clarifications of its press release shortly after its online publication and again 2 days later, citing "internal communications problems." Meanwhile, the findings were prominently reported in the national media as a possible solution to the Bush administration's opposition to the use of federal funds for research on new stem-cell lines. A White House spokeswoman was quoted in news reports, however, as saying that the new technique would not resolve the President's ethical concerns about the use of embryos in research. Later the same week, Richard Doerflinger of the U.S. Conference of Catholic Bishops, a prominent critic of such research, e-mailed reporters, charging that the study had been misrepresented. "This experiment left no embryos alive and solves no ethical problems," Doerflinger wrote.
At a hearing of the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies in early September, Lanza received a tongue-lashing from Senator Arlen Specter (R-PA), a strong supporter of stem-cell research. "It's a big black eye if scientists are making false and inaccurate representations," Specter told Lanza.
Lanza maintained that he had been quoted out of context by interviewers and said he had been shocked by the critical response. "Our paper was 100% correct," he said. "It's very clear that there's a lot of politics going on here."
Advanced Cell Technology has had financial troubles, but its stock price experienced a bump after the Nature publication, and company officials are clearly hoping that cell lines made with the use of the technique will become eligible for federal research funding. However, James Battey, Jr., chairman of the NIH Stem Cell Task Force, said he doubted that the new method will silence the concerns of some critics. For example, he said it is not certain that removing a cell from an eight-cell embryo does no harm, even though hundreds of apparently healthy infants have been born from embryos that underwent the procedure for genetic testing. It is also unknown whether a single human blastomere can develop into an embryo, as is possible in animals. "My guess is, absent complete reassurance on these issues, there will be individuals who will find this protocol morally and ethically problematic," Battey predicted.
http://content.nejm.org/cgi/content/full/355/16/1634